Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Ascending-Dose Short and Long Intravenous Infusion Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS- 962212 in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs BMS 962212 (Primary) ; Aspirin
- Indications Unspecified
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 29 Jun 2017 New trial record